Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Search
Boehringer Ingelheim Academy Video 2023
Video providing an overview of Boehringer Ingelheim’s Academy initiative and how this networking program facilitates conversations across the innovation community.
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Boehringer Ingelheim Fremont Employee Benefit Highlights
BI Fremont offers an excellent, competitive benefit package that takes care of you & your family. Our benefits package reflects BI’s culture & core values.
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
About Boehringer Ingelheim Academy
About Boehringer Ingelheim Academy
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Manufacturing & Supply Chain
Manufacturing & Supply Chain
Engineering & Facilities
Engineering & Facilities
Partnering Interests
Partnering Interests
Gastrointestinal Cancers
Gastrointestinal Cancers
Skin and Inflammatory Diseases
skin diseases
Science & Innovation
Our Science
Biopharma Contract Manufacturing
Biopharma Contract Manufacturing
Retinal Diseases
Retinal Diseases
Management Rotation | Academic Programs
Management Rotation Program